Cargando…
Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases
Hepatocellular carcinoma (HCC) with lung metastasis is associated with poor prognosis and poor therapeutic outcomes. Studies have demonstrated that stiffened stroma can promote metastasis in various tumors. However, how the lung mechanical microenvironment favors circulating tumor cells remains uncl...
Autores principales: | Liu, Mingyu, Xie, Lulu, Zhang, Yuying, Chen, Jianning, Zhang, Xiang, Chen, Ye, Huang, Wensou, Cai, Mingyue, Liang, Licong, Lai, Miaoling, Huang, Jingjun, Guo, Yongjian, Lin, Liteng, Zhu, Kangshun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839779/ https://www.ncbi.nlm.nih.gov/pubmed/36639658 http://dx.doi.org/10.1038/s41419-023-05550-4 |
Ejemplares similares
-
Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study
por: Huang, Jingjun, et al.
Publicado: (2022) -
Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma
por: Huang, Jingjun, et al.
Publicado: (2021) -
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma
por: Huang, Jingjun, et al.
Publicado: (2021) -
Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Cai, Mingyue, et al.
Publicado: (2022) -
Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)